Lyell Immunopharma Q3 2024 Earnings Report

Lyell Immunopharma EPS Results

• Actual EPS: -$3.40
• Consensus EPS: -$4.00
• Beat/Miss: Beat by +$0.60
• One Year Ago EPS: N/A

Lyell Immunopharma Revenue Results

• Actual Revenue: $0.03 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Lyell Immunopharma Announcement Details

• Quarter: Q3 2024
• Date: 11/7/2024
• Time: N/A
• Conference Call Date: Thursday, November 7, 2024
• Conference Call Time: 4:00PM ET

Lyell Immunopharma (NASDAQ:LYEL), a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.